Improving Variance Estimation for Covariate Adjustment with Binary Outcomes
Listen
Radio episode about this paper
Transcript
Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.
Tom: We're looking at the paper: "Improving Variance Estimation for Covariate Adjustment with Binary Outcomes".
Jane: Here's the gist of the paper. Improving Variance Estimation for Covariate Adjustment with Binary Outcomes proposes an influence function-based leave-one-out cross-validated (IF-LOO) variance estimator for the standardized difference-in-means average treatment effect to provide appropriate type-I error control in challenging settings like rare events or small sample sizes <ref:2605.06655#pg14>.
Tom: Covariate adjustment is recommended by the FDA when baseline variables are prognostic for the primary outcome, and this paper focuses on estimating variance for binary outcomes when marginal outcome probabilities are close to 0 or 1 <ref:2605.06655#pg14>.
Jane: The authors address how to reliably estimate variance for the standardized difference-in-means average treatment effect <ref:2605.06655#pg14>.
Tom: Existing methods, such as those proposed by Ge et al.
Paper summary: Tom: So we're looking at this paper titled Improving Variance Estimation for Covariate Adjustment with Binary Outcomes, and it's about how to get a reliable way to estimate the variance for that standardized difference-in-means average treatment effect.
Jane: That sounds really technical, but the core idea is that when you have binary outcomes—like yes or no—and your event rates are either very low or your sample size is small, standard methods for estimating the variance can actually give you wrong confidence intervals.
Lu: Yeah, the authors focus on that specific problem because covariate adjustment itself is recommended by the FDA when those baseline variables predict what happens next, and they're looking at how to handle that standardization method correctly when probabilities are near zero or one.
Meng: But what they claim is they propose a new approach called an influence function-based leave-one-out cross-validated estimator, which is their IF LOO variance estimator.
Tom: Right, so the big claim here is that this IF LOO method provides appropriate type one error control for the standardized treatment effect variance in those tricky settings.
Jane: And they back it up with simulation studies showing that in both a moderate sample size scenario and a small sample size scenario, this IF LOO estimator performs much better than other methods like the IF plug-in or RobinCar2.
Lu: They show that when the sample size is two hundred fifty and the placebo rate is low at two point five percent, this estimator gives coverage near the nominal level across all data generating processes, whereas IF plug-in and RobinCar2 show undercoverage at low true average treatment effects.
Tom: That's a big deal because it means in those challenging situations, you can actually trust the standard error estimates more than you could with those other methods.
Jane: And then they look at the small sample scenario, where the sample size is fifty and the placebo rate is higher at twenty-five percent. In that case, IF plug-in and RobinCar2 show substantial undercoverage, with type one error coverage as high as eighteen percent at the null.
Meng: So what they find is that IF LOO and even an unadjusted analysis show only modest undercoverage in the small sample setting, which is a pretty significant improvement over what other methods showed.
Paper summary: Tom: It sounds like this IF LOO variance estimator solves a real problem where existing methods fail to provide adequate coverage or suffer from computational issues when event rates are low or samples are small.
Jane: The methodology they're using is based on an influence function approach, extending a previously proposed plug-in based variance estimator and drawing on the history of cross fit and cross validated estimators in semiparametric statistics.
Lu: They define their IF LOO variance as sigma squared IF LOO, which involves a sum over n squared times a specific term involving the leave one out prediction and the standardized treatment effect.
Tom: They also provide a theorem showing that this proposed estimator is square root n consistent and asymptotically normal, converging to N zero with variance equal to W, which is defined as the variance of phi of O squared.
Jane: That consistency proof shows that as the sample size goes to infinity, this estimator reliably converges to the true asymptotic variance W.
Meng: From a deployment standpoint, what's interesting for me is that because it has a closed form expression, it avoids computational instability and sampling errors you often see with bootstrap methods.
Tom: That's good because if we were trying to deploy this in production where we need fast estimates, avoiding those kinds of errors in the variance calculation is definitely something I'd look for.
Lu: The paper also emphasizes that the correctly specified model achieves the minimum proper variance, which connects back to the semiparametric efficiency bound, and they suggest IF LOO performs best in small samples where overfitting is most pronounced due to many covariates relative to observations.
Jane: So while it's good for small samples, they also note that in large samples with non-rare event rates, the differences between various variance estimators tend to disappear, making the issue less of a concern.
Tom: It seems like this paper is really focusing on finding a robust way to estimate uncertainty when dealing with binary outcomes and covariate adjustment.
Jane: And it suggests that for those situations, the IF LOO approach could be a prudent default choice to make sure your inferences are valid, especially when you're not sure about the true event rate.
Paper summary: Lu: Looking ahead, they mention a few things: first, applying finite sample corrections to these asymptotic estimates to fix some of the coverage issues seen in simulations.
Meng: And another area they suggest exploring is how these methods relate to randomization-based inference, which is something Magirr et al. suggested in two thousand twenty-five <ref:2605.06655#pg1>.
Tom: They also hint that exact tests might integrate covariate adjustment by linearizing the test statistic, which could be useful for more specific applications than just variance estimation.
Jane: The paper also flags that with binary covariates, the under-coverage of overfit models seems to be a bigger issue compared to when you have continuous variables.
Lu: Overall, they compare IF LOO against the influence function plug-in, ANHECOVA estimator, and the nonparametric bootstrap, and in both simulation scenarios—the N two hundred fifty and N fifty cases—IF LOO offers an improvement over the IF plug-in and RobinCar2 variance estimators.
Tom: So to wrap up this whole discussion about Improving Variance Estimation for Covariate Adjustment with Binary Outcomes, it seems the main message is that for binary outcomes where event rates are low or sample sizes are small, you should look beyond the standard methods because they can give you unreliable coverage.
Jane: And the authors strongly suggest that their IF LOO variance estimator is a better option because it handles those finite sample problems more robustly than its counterparts.
Lu: The consistency proof confirms that this estimator converges to the true asymptotic variance W, and it does so by analyzing the error term components, showing Term A converges to a Normal distribution while Terms B and C go to zero in probability as n goes to infinity.
Meng: For me, what matters is that if we're deploying this on real traffic at scale, we need something computationally stable, and the authors are right about that because it has a closed form expression instead of relying on complex sampling procedures.
Tom: So the whole point here is moving toward estimators that are grounded in asymptotic theory but specifically designed to handle the practical limitations we see in finite samples for these types of models.
Jane: It's about making sure that when we use covariate adjustment for binary outcomes, especially when things are sparse, our confidence intervals actually reflect what they should be.
Conclusion: Tom: So, we’re wrapping up this deep dive into "Improving Variance Estimation for Covariate Adjustment with Binary Outcomes."
Jane: It boils down to fixing a problem where standard ways of calculating the variance for those treatment effects get messed up when your data is binary and you have few events.
Tom: Right. The authors, they’re looking at how to get a reliable measure of uncertainty when you can't rely on the usual rules for continuous outcomes.
Jane: They propose this leave one out cross validated estimator, which they call the IF LOO variance estimator. It uses influence functions and cross fitting history to do this.
Tom: The main point is that in tough spots, like rare events or small samples, this method gives you much better type one error control than older plug-in approaches.
Jane: They did simulations showing that this IF LOO method handles both moderate sample sizes and very small ones really well, achieving good coverage where others failed.
Tom: It suggests that for clinical trials or any situation where covariate adjustment is necessary with binary results, this estimator is a much safer default choice.
Jane: It's grounded in some solid asymptotic theory, proving it converges to the true variance as the sample size gets bigger.
Tom: So, it’s about moving away from methods that just work okay in big samples and toward something that actually works when things are sparse.
Jane: And while it’s strong for small samples, they also point out that you still need to be careful with how you specify your model itself.
Tom: Exactly. The paper hints that the way you structure your data generating process really matters, and if the model isn't right, no variance estimator is going to save you.
Jane: That leads us next into how they actually built this thing—the specific math behind that leave one out term.
University of California, Berkeley · Hoffmann La Roche Ltd. · Genentech South San Francisco, CA. · Johns Hopkins University Baltimore, MD.
stat.ME
Submitted: 2026-05-07
Updated: 2026-11-12
Code: https://github.com/openpharma/RobinCar2
License: http://creativecommons.org/licenses/by/4.0/
Importance score: 91/100
The gist: Improving Variance Estimation for Covariate Adjustment with Binary Outcomes proposes an influence function-based leave-one-out cross-validated (IF-LOO) variance estimator for the standardized…
Key concepts
- Covariate Adjustment
- This is the process of statistically controlling for the influence of baseline variables (covariates) on the primary outcome. It is recommended by regulatory bodies like the FDA when those baseline variables are known to affect the final result, ensuring that observed effects are truly due to treatment rather than pre-existing differences.
- Standardized Difference-in-Means Average Treatment Effect
- This measures how much a treatment changes the average outcome, after accounting for the influence of covariates. Standardizing it helps compare effects across different groups or settings by putting the effect into a common scale, which is crucial for accurate inference.
- Influence Function-based Leave-One-Out (IF-LOO) Estimator
- This is a novel variance estimator that uses the history of cross-fitting and cross-validation to calculate uncertainty. It works by systematically leaving out one data point at a time to estimate the variance, which helps prevent overfitting and provides more accurate results than simpler methods, particularly in small samples.
Terminology
Summary
Improving Variance Estimation for Covariate Adjustment with Binary Outcomes proposes an influence function-based leave-one-out cross-validated (IF-LOO) variance estimator for the standardized difference-in-means average treatment effect to provide appropriate type-I error control in challenging settings like rare events or small sample sizes <ref:2605. p. 0 We propose an influence
function-based leave-one-out cross-validated (IF-LOO) variance estimator for the standardized difference-in-means average treatment effect. Through simulation studies, we show that
this estimator provides appropriate type-I error control and performs reliably in challenging settings where existing methods can yield inflated type-I error or fail entirely, such as
when outcome events are rare or sample sizes are small.Where the paper says it
Motivation and Problem Statement
Covariate adjustment is recommended by the FDA when baseline variables are prognostic for the primary outcome, and this paper focuses on estimating variance for binary outcomes when marginal outcome probabilities are close to 0 or 1 <ref:2605.06655#pg14>. The authors address how to reliably estimate variance for the standardized difference-in-means average treatment effect <ref:2605. p. 0 We address the question of how to reliably estimate variance for binary
outcomes when marginal outcome probabilities are close to 0 or 1. We propose an influence
function-based leave-one-out cross-validated (IF-LOO) variance estimator for the standardized difference-in-means average treatment effect. Through simulation studies, we show that
this estimator provides appropriate type-I error control and performs reliably in challenging settings where existing methods can yield inflated type-I error or fail entirely, such as
when outcome events are rare or sample sizes are small. In addition to having desirable
statistical properties, we derive a closed-form expression for the proposed estimator, enabling
straightforward and reliable implementation by study statisticians. (2023), which demonstrated that the variance estimation
approach previously proposed by Ge et al. (2011) neglects a component of the variance, leading to
underestimation. explorations of the variance estimators for covariate adjustment when designing a phase III clinical
trial, we uncovered that when event rates are low or the sample size is small, the proposed variance
estimators for standardization either fail to obtain adequate coverage or suffer from computational
drawbacks, which inspired us to develop a new approach. Therefore, in this manuscript, we
propose a novel influence function-based leave-one-out (IF-LOO) estimate of the variance for the
standardized treatment effect, which is an extension of a previously proposed influence function
plug-in based variance estimator (Rosenblum and van Der Laan, 2010).Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Proposed Methodology
The authors propose a novel influence function-based leave one out (IF-LOO) estimate of the variance for the standardized treatment effect, which extends a previously proposed influence function plug-in based variance estimator <ref:2605.06655#pg14>. This estimator draws on the history of using cross fit and cross validated estimators in semiparametric statistics <ref:2605. p. 2 Therefore, in this manuscript, we
propose a novel influence function-based leave-one-out (IF-LOO) estimate of the variance for the
standardized treatment effect, which is an extension of a previously proposed influence function
plug-in based variance estimator (Rosenblum and van Der Laan, 2010). This estimator draws on
the history of using cross-fit and cross-validated estimators in semiparametric statistics (e. We address the question of how to reliably estimate variance for binary
outcomes when marginal outcome probabilities are close to 0 or 1. We propose an influence
function-based leave-one-out cross-validated (IF-LOO) variance estimator for the standardized difference-in-means average treatment effect. Then, we define
σb
2
IF-LOO =
1
n2
Xn
i=1
φb
2
−i
, (7)
where
φb−i =
Ai
π0
−
1 − Ai
1 − π0
Yi − µb−i(Ai
, Xi)
+ µb−i(1, Xi) − µb−i(0, Xi) − bθstandardized. In addition, we present the following theorem, stating that the proposed estimator is √
n consistent
and asymptotically normal:
Theorem 1.Where the paper says it
Where the paper says it
Where the paper says it
Simulation Results and Performance
The authors conduct simulation studies in two scenarios: a moderate sample size (N=250) with a low placebo rate (2.5%) and a small sample size (N=50) with a larger placebo rate (25%) <ref:2605. p. 6 The first is a scenario with a moderate sample size (N = 250) and a small
marginal placebo rate of the outcome in the population (2. The second is a scenario with a
smaller sample size (N = 50) and a larger marginal placebo rate of the outcome in the population
(25%). Bootstrap exhibits slight overcoverage at low true ATE values, while IF Plug-In
and RobinCar2 continue to undercover at low true ATE values, though the degree of undercoverage
is substantially attenuated relative to the N = 50 scenario and both converge toward the nominal
level as the true ATE increases. This attenuation is expected: as the sample size grows, the overfitting bias in the plug-in variance estimator shrinks, and the advantage of the LOO correction
diminishes. We next consider the more challenging scenario: a small sample size of N = 50 with a placebo
rate of 25% (Figure 2). In this setting, IF Plug-In and RobinCar2 exhibit substantial undercoverage
across all DGPs, with type-I error coverage as high as 18% at the null.Where the paper says it
Where the paper says it
Where the paper says it
Advantages and Conclusion
The IF-LOO approach is shown to perform better than standard methods in finite samples, particularly when overfitting is pronounced due to many covariates relative to the number of observations <ref:2605.06655#pg14>. Advantages include enabling unambiguous exact matching in clinical trial programming implementations and allowing for easy employment of machine learning algorithms for plug-in predictions <ref:2605.06655#pg14>. Overall, the IF-LOO variance estimator solves issues faced in covariate adjustment with binary outcomes, suggesting it is a prudent default choice to ensure valid inferences <ref:2605. p. 0 The robust finite-sample
performance and ease of implementation suggest the IF-LOO variance estimator is a prudent
default choice for standardization in clinical trials. Keywords: Covariate Adjustment, Standardization, G-computation, Influence Function, LeaveOne-Out Estimator
1 Introduction
Using baseline covariate information to increase efficiency and gain power in statistical analyses of
randomized trials is a long-standing idea dating back to Fisher (1934). The influence function
of bθstandardized in equation 3 is the efficient influence function φef f and obtains this bound if the
working model is correctly specified. Despite being grounded in rigorous asymptotic statistical theory, as we show in Section 3, this
IF-based variance estimator (along with others proposed in the current literature) can underestimate variance in certain finite-sample scenarios which researchers may plausibly face when running
a randomized control trial, leading to invalid type-I error control.Where the paper says it
Where the paper says it
Proof of Consistency
The proof of Theorem 1 shows that the IF-LOO estimator converges to the true asymptotic variance V0 by analyzing the components of the error term, showing that Term A converges to a Normal distribution, while Terms B and C converge in probability to 0 as n → ∞ <ref:2605.06655#pg14>. This rigorous proof confirms that √n consistent with asymptotic variance W = Var(φ(O)2) <ref:2605. p. 4 The influence function
of bθstandardized in equation 3 is the efficient influence function φef f and obtains this bound if the
working model is correctly specified. Despite being grounded in rigorous asymptotic statistical theory, as we show in Section 3, this
IF-based variance estimator (along with others proposed in the current literature) can underestimate variance in certain finite-sample scenarios which researchers may plausibly face when running
a randomized control trial, leading to invalid type-I error control. By employing leaveone-out, we prevent such overfitting by ensuring the prediction for individual i is generated using
a model that was trained on all data except for that from individual i. Let µb−i(a, x) be the predictions from a fitted working logistic regression model using all of the
available data excluding individual i (n − 1 data points).Where the paper says it
Where the paper says it
Data Generating Process Structure
The simulation studies utilize a specific data generating process where covariates X1-X4 are iid∼ Unif(0, 1) and X5-X6 are iid∼ Bernoulli(p = 1/2) <ref:2605.06655#pg14>. The treatment assignment A is also modeled as Bernoulli(p = 1/2), and the outcome Y A, X is binary with log odds linear in all six covariates and the treatment <ref:2605. p. 6 The treatment is assigned via a random coin flip. The outcome is
a binary variable where the log odds is linear in all six covariates and the treatment. We write
µ
∗
(a, x) = expit(mβ
∗ (a, x)) to represent the logistic regression model with the true coefficients β
∗
. They also show that the influence function of the standardized estimator is given by
φ(O) = A
π0
−
1 − A
1 − π0
(Y − µ
∗
(A, X)) + µ
∗
(1, X) − µ
∗
(0, X) − θAT E. This is
not only because the method was highlighted by the FDA in their covariate adjustment guidance
(U. Food and Drug Administration, 2023), but also because it allows statisticians to perform a
1
arXiv:2605. We
consider two hypothetical randomized control trials with two data generating processes (DGPs)
to highlight the types of scenarios in which researchers would gain the most from the IF-LOO
variance estimator. The first is a scenario with a moderate sample size (N = 250) and a small
marginal placebo rate of the outcome in the population (2.Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Future Research Directions
A number of avenues for future research include applying finite sample corrections to asymptotic-based variance estimates to fix under coverage issues revealed in simulations <ref:2605.06655#pg14>. Exploring the relationship between these methods and randomization-based inference should be deepened, as suggested by Magirr et al. p. 1 In addition,
this particular paper did not consider other variance estimators proposed in the literature. A more
realistic simulation study was conducted by Liu & Xi which compared nine different variance estimators with much more comparable results among approaches, but still corroborating Ye’s claims
that those based the delta method have a tendency to provide anti-conservative inference (Liu and
Xi, 2024). This is
not only because the method was highlighted by the FDA in their covariate adjustment guidance
(U. Food and Drug Administration, 2023), but also because it allows statisticians to perform a
1
arXiv:2605. However, notably absent from the literature are studies that have explicitly considered how
the various variance estimators perform in scenarios with low event rates or small sample sizes,
which are situations encountered in many randomized clinical trials. While exact procedures such
as Fisher’s (1934) or the Suissa-Shuster (1985) test are well-formulated to handle the small sample
setting for binary outcomes, they cannot reap the benefits of covariate adjustment. The second is a scenario with a
smaller sample size (N = 50) and a larger marginal placebo rate of the outcome in the population
(25%). In each of the two scenarios, each individual observation consists of six independent covariates:
four continuous and two binary.Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Model Specification and Efficiency
The paper emphasizes that the correctly specified model achieves the minimum proper variance, which corresponds to the semiparametric efficiency bound <ref:2605.06655#pg14>. The IF-LOO estimator seems to perform best especially in small samples and those with low event rates where overfitting is most pronounced <ref:2605. p. 2 explorations of the variance estimators for covariate adjustment when designing a phase III clinical
trial, we uncovered that when event rates are low or the sample size is small, the proposed variance
estimators for standardization either fail to obtain adequate coverage or suffer from computational
drawbacks, which inspired us to develop a new approach. Therefore, in this manuscript, we
propose a novel influence function-based leave-one-out (IF-LOO) estimate of the variance for the
standardized treatment effect, which is an extension of a previously proposed influence function
plug-in based variance estimator (Rosenblum and van Der Laan, 2010). Food and Drug Administration, 2023). However, notably absent from the literature are studies that have explicitly considered how
the various variance estimators perform in scenarios with low event rates or small sample sizes,
which are situations encountered in many randomized clinical trials. This leads to having to throw out some
bootstrap samples, leading to an invalid bootstrap distribution. Because the IF-LOO variance has
a closed-form expression, it avoids the computational instability and sampling errors associated
with the bootstrap. This is
not only because the method was highlighted by the FDA in their covariate adjustment guidance
(U. Food and Drug Administration, 2023), but also because it allows statisticians to perform a
1
arXiv:2605.Where the paper says it
Where the paper says it
Where the paper says it
Where the paper says it
Benchmark Estimators Comparison
The performance of IF-LOO is compared against three benchmark estimators: the influence-function based estimator (IF plug-in), the analysis of heterogeneous covariance (ANHECOVA) estimator, and the nonparametric bootstrap <ref:2605.06655#pg14>. In both simulation scenarios, IF-LOO offers a meaningful improvement over IF Plug-In and RobinCar2 variance estimators in finite samples <ref:2605. p. 8 analysis both exhibit modest undercoverage, with coverage remaining stable between 93% and 94%
across the range of true ATE values. Taken together, the simulation results suggest that IF-LOO offers a meaningful improvement
over the IF plug-in and RobinCar2 variance estimators in finite samples, particularly in the small
sample, higher placebo rate regime where overfitting is most pronounced. Taken together, the simulation results suggest that IF-LOO offers a meaningful improvement
over the IF plug-in and RobinCar2 variance estimators in finite samples, particularly in the small
sample, higher placebo rate regime where overfitting is most pronounced. Bootstrap performs
comparably to IF-LOO in terms of coverage. In addition to having desirable
statistical properties, we derive a closed-form expression for the proposed estimator, enabling
straightforward and reliable implementation by study statisticians. The robust finite-sample
performance and ease of implementation suggest the IF-LOO variance estimator is a prudent
default choice for standardization in clinical trials.Where the paper says it
Where the paper says it
Where the paper says it
Green — the paper says it, and the page is printed. Red — no passage carries it, so treat that sentence as unverified. The same check runs on your own text: check a summary against its source, $5.
Improvements for AI systems
-
Improve variance estimation reliability for covariate adjustment in binary outcomes by replacing traditional influence function based estimators with a leave one out cross validated (IF-LOO) estimator, which is shown to provide
more reliable coverage and proper type-I error control as compared to standard methods proposed in the literature.
-
Enable robust inference when event rates are low or sample sizes are small by utilizing the IF-LOO variance estimator, which addresses the issue that existing methods
can yield inflated type-I error or fail entirely, such as when outcome events are rare or sample sizes are small.
-
Facilitate deterministic analysis in clinical trial programming by using a LOO based estimator, as it
enables unambiguous exact matching because it does not involve any repeated sampling,
unlike cross validation whichhas been shown to lead to convergence issues in finite-samples.
Abstract
Covariate adjustment is a general method for improving precision when estimating treatment effects in randomized trials and is recommended by the FDA in its 2023 guidance when baseline variables are prognostic for the primary outcome. We focus on a method highlighted in that guidance called ``standardization" (or ``g-computation") for estimating the marginal treatment effect. We address the question of how to reliably estimate variance for binary outcomes when marginal outcome probabilities are close to 0 or 1. We propose an influence function-based leave-one-out cross-validated (IF-LOO) variance estimator for the standardized difference-in-means average treatment effect. Through simulation studies, we show that this estimator provides appropriate type-I error control and performs reliably in challenging settings where existing methods can yield inflated type-I error or fail entirely, such as when outcome events are rare or sample sizes are small. In addition to having desirable statistical properties, we derive a closed-form expression for the proposed estimator, enabling straightforward and reliable implementation by study statisticians. The robust finite-sample performance and ease of implementation suggest the IF-LOO variance estimator is a prudent default choice for standardization in clinical trials.
Sources
- Cross-Fitting and Fast Remainder Rates for Semiparametric Estimation
- Revealing the Truth: Calculating True Values in Causal Inference Simulation Studies via Gaussian Quadrature
- How should covariates be handled in randomized trials? Empirical evidence from 50 trials and recommendations for practice
Related papers
- Learning Robust Treatment Rules for Censored Data
- Neural Estimation of Summary Statistics for Simulation-Based Inference with Non-Asymptotic Guarantees
- Spectral divide-and-conquer MCMC for long stationary time series
- Improving the Efficiency of Subgroup Analysis in Randomized Controlled Trials with TMLE
- Personalized Federated Vector Autoregression with Personalization Diversity
- Doubly Robust and Efficient Calibration of Prediction Sets for Right-Censored Time-to-Event Outcomes